TNT Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==TNT Trial== ===Objective=== To compare the efficacy of 10 mg and 80 mg daily dose of atorvastatin in patients with stable..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To compare the efficacy of 10 mg and 80 mg daily dose of [[atorvastatin]] in patients with stable CAD and baseline LDL-C between 130 mg/dL and 250 mg/dL. | To compare the efficacy of 10 mg and 80 mg daily dose of [[atorvastatin]] in patients with stable CAD and baseline LDL-C between 130 mg/dL and 250 mg/dL. | ||
==Methods== | |||
The Treating to New Targets (TNT) trial was a randomized trial that enrolled 10,001 patients with stable coronary artery disease to treatment with atorvastatin, 80 or 10 mg/dL, and followed them up for a median period of 4.9 years. The primary end point was a composite of cardiovascular death, [[myocardial infarction]], resuscitated cardiac arrest, and [[stroke]]. | The Treating to New Targets (TNT) trial was a randomized trial that enrolled 10,001 patients with stable coronary artery disease to treatment with atorvastatin, 80 or 10 mg/dL, and followed them up for a median period of 4.9 years. The primary end point was a composite of cardiovascular death, [[myocardial infarction]], resuscitated cardiac arrest, and [[stroke]]. | ||
==Results== | |||
Compared to low dose, high dose atorvastatin was associated with: | Compared to low dose, high dose atorvastatin was associated with: | ||
* A significantly lower mean serum LDL-C concentration (77 vs 101 mg/dL) | * A significantly lower mean serum LDL-C concentration (77 vs 101 mg/dL) | ||
| Line 16: | Line 15: | ||
* No reduction in all-cause mortality. Higher doses of atorvastatin, although reduced mortality due to cardiac events, were associated with higher mortality rate due to noncardiovascular events. | * No reduction in all-cause mortality. Higher doses of atorvastatin, although reduced mortality due to cardiac events, were associated with higher mortality rate due to noncardiovascular events. | ||
==Conclusion== | |||
Wider use of the 80-mg dose of atorvastatin in patients with stable coronary disease is safe, cost-effective, and provides an incremental reduction in coronary events.<ref name="pmid19410683">{{cite journal |author=Waters DD |title=Clinical insights from the Treating to New Targets trial |journal=[[Progress in Cardiovascular Diseases]] |volume=51 |issue=6 |pages=487–502 |year=2009 |pmid=19410683 |doi=10.1016/j.pcad.2009.01.001 |url=}}</ref> | Wider use of the 80-mg dose of atorvastatin in patients with stable coronary disease is safe, cost-effective, and provides an incremental reduction in coronary events.<ref name="pmid19410683">{{cite journal |author=Waters DD |title=Clinical insights from the Treating to New Targets trial |journal=[[Progress in Cardiovascular Diseases]] |volume=51 |issue=6 |pages=487–502 |year=2009 |pmid=19410683 |doi=10.1016/j.pcad.2009.01.001 |url=}}</ref> | ||
| Line 25: | Line 24: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Latest revision as of 23:28, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
TNT Trial On the Web |
|
American Roentgen Ray Society Images of TNT Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To compare the efficacy of 10 mg and 80 mg daily dose of atorvastatin in patients with stable CAD and baseline LDL-C between 130 mg/dL and 250 mg/dL.
Methods
The Treating to New Targets (TNT) trial was a randomized trial that enrolled 10,001 patients with stable coronary artery disease to treatment with atorvastatin, 80 or 10 mg/dL, and followed them up for a median period of 4.9 years. The primary end point was a composite of cardiovascular death, myocardial infarction, resuscitated cardiac arrest, and stroke.
Results
Compared to low dose, high dose atorvastatin was associated with:
- A significantly lower mean serum LDL-C concentration (77 vs 101 mg/dL)
- Significant reductions in the rate of the primary end point (8.7 vs 10.9 percent)
- No reduction in all-cause mortality. Higher doses of atorvastatin, although reduced mortality due to cardiac events, were associated with higher mortality rate due to noncardiovascular events.
Conclusion
Wider use of the 80-mg dose of atorvastatin in patients with stable coronary disease is safe, cost-effective, and provides an incremental reduction in coronary events.[1]
References
- ↑ Waters DD (2009). "Clinical insights from the Treating to New Targets trial". Progress in Cardiovascular Diseases. 51 (6): 487–502. doi:10.1016/j.pcad.2009.01.001. PMID 19410683.